Members of the ESRC-funded REGenableMED project have published a Policy Briefing which explores a number of key factors that are likely to determine the reimbursement of regenerative medicine therapies as they move towards the clinic. The Briefing outlines those factors that are specific to the UK as well as more widely, and concludes with a series of priorities that policy needs to address.
Many researchers and clinicians believe that stem cells will one day be used in regenerative medicines to treat many injuries and diseases, including Huntington’s disease (HD). Researchers think that nerve cells that die in HD patients may be able to be replaced with new healthy neurons made from stem cells. Scientists are already able to use stem cells to create nerve cells similar to those lost by HD patients.
Kim Jensen is Associate Professor at the Biotech Research & Innovation Centre (BRIC), Universty of Copenhagen, Denmark. Here, he talks about his scientific career past, present and future in the field of epithelial stem cell research.